Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Relies On New Products For Fiscal Second-Half Boost

This article was originally published in The Tan Sheet

Executive Summary

Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts